Alexion ends Moderna mRNA pact

By Flora Southey

Alexion Pharmaceuticals says it is reducing R&D operations and terminating mRNA-focused preclinical partnerships.

The cell therapy oncology market is expected to reach $30bn by 2030. (Image: iStock)

GE acquires stem cell supplier Biosafe

By Melissa Fassbender

GE Health has acquired Biosafe in a move that it says will enable production of cell and gene therapies on an industrialized scale.

The additions come in response to a growing demand for immuno-oncology services (Image: iStock/royaltystockphoto)

CrownBio expands immuno-oncology offerings

By Melissa Fassbender

Crown Bioscience has expanded its immuno-oncology platform at its facilities in Europe, the US, and Asia to include immunophenotyping analysis.

Bristol-Myers Squibb has completed an expansion at its Devens, MA, biologics facility. (Photo: Business Wire)

BMS expands biologics facility in MA

By Melissa Fassbender

Bristol-Myers Squibb (BMS) has completed an expansion of its Devens, MA-based biologics facility to support the company’s growing biologics medicines portfolio.